Emerging pharmacotherapy for cancer patients with cognitive dysfunction

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Davis, Justin ^a   Ahlberg, Fiona M ^a   Berk, Michael ^a,c   Ashley, David M ^a,b   Khasraw, Mustafa ^a,b,d  

^a DEAKIN UNIVERSITY   (Australia)

^b GEELONG HOSPITAL   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Cancer; Chemotherapy; Cognitive dysfunction; Cognitive impairment; Pharmacotherapy

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ACETIC ACID DERIVATIVE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CATECHIN; CURCUMIN; CYSTEINE; DONEPEZIL; FLUOROURACIL; GLITAZONE DERIVATIVE; GLUCOCORTICOID; LITHIUM; MEMANTINE; METHOTREXATE; METHYLPHENIDATE; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; RESVERATROL; ROSIGLITAZONE;

ADDICTION; ALZHEIMER DISEASE; AMNESIA; ANXIETY; APPETITE; BIPOLAR DISORDER; CANCER PATIENT; CELL CULTURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; HALLUCINATION; HUMAN; MEMORY; METASTASIS; MOOD; NEUROPROTECTION; NONHUMAN; PATIENT; RESTLESSNESS; REVIEW; SIDE EFFECT; SKULL IRRADIATION; SWEATING; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; INDANS; MEMANTINE; NEOPLASMS; PIPERIDINES;

EID: 84886004883     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-153     Document Type: Review

References (64)

1. Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliative & supportive care 2007, 5(03):273-280.
2. Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D'Alonzo M, Sismondi P, Torta R. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl) 2012, 21(4):485-492. doi: 10.1111/j.1365-2354.2011.01320.x. Epub 2011 Dec 28, 10.1111/j.1365-2354.2011.01320.x, 22211832.
3. Dutta V. Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. J Cancer Res Ther 2011, 7(3):264. 10.4103/0973-1482.87008, 22044805.
4. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011, 12(7):703-708. doi: 10.1016/S1470-2045(10)70294-1. Epub 2011 Feb 25, 10.1016/S1470-2045(10)70294-1, 21354373.
5. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Review 2008, 18(2):121-131.
6. Batalo M, Nagaiah G, Abraham J. Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors. Expert Rev Anticancer Ther 2011, 11(8):1277-1282. 10.1586/era.11.112, 21916581.
7. Khasraw M, Posner JB. Neurological complications of systemic cancer. Lancet Neurol 2010, 9(12):1214-1227. 10.1016/S1474-4422(10)70220-9, 21087743.
8. Hermelink K. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2011, 117(5):1103-1103.
9. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012, 12(3):267-275. 10.1007/s11910-012-0264-9, 22453825.
10. Correa DD, Hess LM. Cognitive function and quality of life in ovarian cancer. Gynecol Oncol 2012, 124(3):404-409. 10.1016/j.ygyno.2011.11.005, 22094932.
11. Castellino SM, Tooze JA, Flowers L, Hill DF, McMullen KP, Shaw EG, Parsons SK. Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: a pilot study. Pediatr Blood Cancer 2012, 59(3):540-547. doi: 10.1002/pbc.24078. Epub 2012 Jan 11, 10.1002/pbc.24078, 3345166, 22238217.
12. Shaw EG, Rosdhal R, D'Agostino RB, Lovato J, Naughton MJ, Robbins ME, Rapp SR. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006, 24(9):1415-1420. 10.1200/JCO.2005.03.3001, 16549835.
13. Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, Bonner M, Brown R, Xiong X, Wu S, Gururangan S. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 2004, 22(23):4795-4803. 10.1200/JCO.2004.04.128, 15570081.
14. Conklin HM, Khan RB, Reddick WE, Helton S, Brown R, Howard SC, Bonner M, Christensen R, Wu S, Xiong X. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. J Pediatr Psychol 2007, 32(9):1127-1139. 10.1093/jpepsy/jsm045, 17569711.
15. Daly BP, Brown RT. Scholarly literature review: management of neurocognitive late effects with stimulant medication. J Pediatr Psychol 2007, 32(9):1111-1126. 10.1093/jpepsy/jsm012, 17442692.
16. Thompson SJ, Leigh L, Christensen R, Xiong X, Kun LE, Heideman RL, Reddick WE, Gajjar A, Merchant T, Pui CH. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001, 19(6):1802-1808.
17. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Münzel K. Cognitive function during neoadjuvant chemotherapy for breast cancer. Cancer 2007, 109(9):1905-1913. 10.1002/cncr.22610, 17351951.
18. Holmes D. Trying to unravel the mysteries of chemobrain. Lancet Neurol 2013, 12(6):533-534. doi: 10.1016/S1474-4422(13)70087-5. Epub 2013 Apr 19, 10.1016/S1474-4422(13)70087-5, 23602780.
19. Aluise CD, Sultana R, Tangpong J, Vore M, St Clair D, Moscow JA, Butterfield DA. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 2010, 678:147-156. 10.1007/978-1-4419-6306-2_19, 20738017.
20. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 2011, 38(3):431-438. 10.1053/j.seminoncol.2011.03.014, 3120018, 21600374.
21. Liu Y, Xiao S, Liu J, Zhou H, Liu Z, Xin Y, Suo WZ. An experimental study of acute radiation-induced cognitive dysfunction in a young rat model. AJNR Am J Neuroradiol 2010, 31(2):383-387. 10.3174/ajnr.A1801, 19833794.
22. Khasraw M, Lassman AB. Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma. Nat Rev Neurol 2009, 5(12):646-647. 10.1038/nrneurol.2009.194, 19953115.
23. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 2005, 30(2):100-107. 551162, 15798785.
24. Joly F, Rigal O, Noal S, Giffard B. Cognitive dysfunction and cancer: which consequences in terms of disease management?. Psychooncology 2011, 20(12):1251-1258. 10.1002/pon.1903, 21254307.
25. Kim D. Practical use and risk of modafinil, a novel waking drug 2012, 27. Toxicology: Environmental Health and.
26. Gottesmann C. Function of GABAB and r-containing GABAA receptors (GABAC receptors) in the regulation of basic and higher integrated sleep-waking processes. GABA and sleep: molecular, functional and clinical aspects 2010, 169. Basel: Springer, Monti JM.
27. Scammell T, Gerashchenko D, Mochizuki T, McCarthy M, Estabrooke I, Sears C, Saper C, Urade Y, Hayaishi O. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 2001, 107(4):653-663. 10.1016/S0306-4522(01)00383-9, 11720788.
28. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neuroscience letters 1998, 241(2-3):95-98.
29. Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, Roscoe JA, Morrow GR. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009, 115(12):2605-2616. 10.1002/cncr.24287, 2796482, 19309747.
30. Lundorff L, Jonsson B, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliative medicine 2009, 23(8):731-738. 10.1177/0269216309106872, 19648224.
31. Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med 2009, 12(5):433-439. 10.1089/jpm.2008.0230, 19416039.
32. Volkow N, Fowler J, Wang G, Ding Y, Gatley S. Mechanism of action of methylphenidate: insights from PET imaging studies. J Attention Disord 2002, 6:S31.
33. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008, 28(3):S46.
34. Lasheen W, Walsh D, Mahmoud F, Davis MP, Rivera N, Khoshknabi DS. Methylphenidate side effects in advanced cancer: a retrospective analysis. American J Hospice and Palliat Med 2010, 27(1):16-23.
35. Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008, 16(6):577-583. 10.1007/s00520-007-0341-9, 17972110.
36. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain and Symptom Management 2009, 38(5):650-662.
37. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, Wefel JS. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumour. J Neurooncol 2012, 107(1):165-74. doi:10.1007/s11060-011-0723-1. Epub 2011 Oct 2., 10.1007/s11060-011-0723-1, 21964738.
38. Steinberg M, Lyketsos CG. Pharmacological Therapies in Alzheimer's Disease, in Principles and Practice of Geriatric Psychiatry. 2010, Chichester, UK: John Wiley & Sons, Ltd, Abou-Saleh MT, Katona C, Kumar A, 3, doi:10.1002/9780470669600.ch52.
39. Winocur G, Henkelman M, Wojtowicz JM, Zhang H, Binns MA, Tannock IF. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res 2012, 18(11):3112-3121. 10.1158/1078-0432.CCR-12-0060, 22467680.
40. Winocur G, Binns MA, Tannock I. Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology 2011, 61(8):1222-1228. 10.1016/j.neuropharm.2011.07.013, 21803055.
41. Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL, Whetsell WO, Boone B, Shinohara ET, Hallahan DE. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res 2006, 66(23):11179-11186. 10.1158/0008-5472.CAN-06-2740, 17145862.
42. Khasraw M, Ashley D, Wheeler G, Berk M. Using lithium as a neuroprotective agent in cancer patients: review. BMC medicine 2012, Article in press.
43. Inouye M, Yamamura H, Nakano A. Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. J radiat Res 1995, 36(3):203. 10.1269/jrr.36.203, 8558497.
44. Cimarosti H, Rodnight R, Tavares A, Paiva R, Valentim L, Rocha E, Salbego C. An investigation of the neuroprotective effect of lithium in organotypic slice cultures of rat hippocampus exposed to oxygen and glucose deprivation. Neuroscience letters 2001, 315(1):33-36.
45. Yang ES, Lu B, Hallahan DE. Lithium-mediated neuroprotection during cranial irradiation: a phase 1 trial. ASTRO (american society for therapeutic radiology and oncology) - 49th annual conference 2007, Los Angeles CA.
46. Xia F, Yang E, Hallahan D, Lu B. Lithium-mediated neuroprotection during cranial irradiation: a phase I trial. Neuro-oncology 2008, 10(5):887-887.
47. Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: a review 2012, 2. Oncology: Frontiers in.
48. Robbins ME, Payne V, Tommasi E, Diz DI, Hsu FC, Brown WR, Wheeler KT, Olson J, Zhao W. The AT< sub> 1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys 2009, 73(2):499-505. 10.1016/j.ijrobp.2008.09.058, 2631653, 19084353.
49. Berbee M, Fu Q, Sree Kumar K, Hauer-Jensen M. Novel strategies to ameliorate radiation injury: a possible role for tetrahydrobiopterin. Current drug targets 2010, 11(11):1366-1374. 10.2174/1389450111009011366, 3311028, 20583982.
50. Brown PD, Shook S, Laack NN, Wefel JS, Choucair A, Suh JH, Roberge D, Kavadi V, Mehta MP, Watkins-Bruner D. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiation therapy (WBRT): first report of RTOG 0614, a placebo-controlled, double-blind, randomized trial. Int J Radiat Oncol Biol Phys 2012, 84(3):S1-S2.
51. Berk M, Kapczinski F, Andreazza A, Dean O, Giorlando F, Maes M, Yücel M, Gama C, Dodd S, Dean B. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience & biobehavioral reviews 2011, 35(3):804-817. 10.1016/j.neubiorev.2010.10.001, 20934453.
52. Parachikova A, Green KN, Hendrix C, LaFerla FM. Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PloS one 2010, 5(11):e14015. 10.1371/journal.pone.0014015, 2984445, 21103342.
53. Prakash A, Kumar A. Effect of N-acetyl cysteine against aluminium induced cognitive dysfunction and oxidative damage in rats. Basic & clinical pharmacology & toxicology 2009, 105(2):98-104. 10.1111/j.1742-7843.2009.00404.x, 19389043.
54. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer'Äôs disease. Neurology 2001, 57(8):1515-1517. 10.1212/WNL.57.8.1515, 11673605.
55. Lindsay J, Laurin D, Verreault R, Hubert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging. Am J Epidemiol 2002, 156(5):445-453. 10.1093/aje/kwf074, 12196314.
56. Tiwari V, Chopra K. Resveratrol prevents alcohol induced cognitive deficits and brain damage by blocking inflammatory signaling and cell death cascade in neonatal rat brain. J Neurochem 2011, 117(4):678-690.
57. Howes MJR, Perry E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 2011, 28(6):439-468. 10.2165/11591310-000000000-00000, 21639405.
58. Kim J, Lee HJ, Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer'Äôs disease. J Neurochem 2010, 112(6):1415-1430. 10.1111/j.1471-4159.2009.06562.x, 20050972.
59. Reid CM, Storey E, Wong TY, Woods R, Tonkin A, Wang JJ, Kam A, Janke A, Essex R, Abhayaratna WP. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC neurology 2012, 12(1):3. 10.1186/1471-2377-12-3, 3297524, 22315948.
60. Cunningham C, Skelly D. Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?. J Neuroimmune Pharmacol 2012, 7(1):60-73. 10.1007/s11481-011-9312-5, 3280386, 21932048.
61. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG. ADAPT Research Team Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry 2012, 27(4):364-374. doi: 10.1002/gps.2723. Epub 2011 May 10, 3208130, 21560159, ADAPT Research Team.
62. Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 2012, 104(16):1208-1217. 10.1093/jnci/djs318, 22888140.
63. Kang JH, Cook N, Manson JA, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ 2007, 334(7601):987. 10.1136/bmj.39166.597836.BE, 1867896, 17468120.
64. Jaturapatporn D, Isaac MGEKN, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease 2012, Library: The Cochrane.